Virtual Poster Session in NSCLC From Munich - prIME Oncology
Virtual Poster
Virtual Poster

Virtual Poster Session in NSCLC From Munich

Practical Application of Key Data Presented During the 2018 European Oncology Congress

Not a member of My prIME? Join now for instant access.

View CME-certified poster presentations and downloadable slides covering the most up-to-date clinical trial data on non-small cell lung cancer (NSCLC) from the 2018 European Oncology Congress in Munich.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

0.75 AMA PRA Category 1 Credits™

Release Date

Release Date

Nov 1, 2018

Expiration Date

Nov 2, 2019

Federico Cappuzzo, MD, PhD

Abstract #LBA53: IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC

Featured Expert: Federico Cappuzzo, MD, PhD

Fabrice Barlesi, MD, PhD

Abstract #LBA54: IMpower132: efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC)

Featured Expert: Fabrice Barlesi, MD, PhD

Luis Paz-Ares, MD

Abstract #LBA62: Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: data from KEYNOTE-407

Featured Expert: Luis Paz-Ares, MD

Roy S. Herbst, MD, PhD

Abstract #LBA63: Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed 2 years of pembrolizumab (pembro)

Featured Expert: Roy S. Herbst, MD, PhD

Fabrice Barlesi, MD, PhD

Abstract #1469P: EVIDENS: An observational study of nivolumab-treated patients in advanced non-small cell lung cancer (NSCLC) in a real-world setting: Initial results on 1394 patients

Featured Expert: Fabrice Barlesi, MD, PhD

  • Fabrice Barlesi, MD, PhDAssitance Publique
    Hôpitaux De Marseille
    Marseille, France
  • Federico Cappuzzo, MD, PhDAUSL della Romagna
    Ravenna, Italy
  • Roy S. Herbst, MD, PhDYale Cancer Center
    New Haven, Connecticut, United States
  • Luis Paz-Ares, MDHospital Universitario 12 de Octubre
    Madrid, Spain

This activity is specifically designed for physicians, nurses, and other clinicians who are cancer specialists.

After successful completion of this educational activity, participants should be able to:

  • Discuss key NSCLC data from the conference
  • Apply key NSCLC data from the conference to clinical practice, as appropriate

GI

Colorectal Cancer

Abstract #LBA18_PR: Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)
Featured Expert: Heinz-Josef J. Lenz, MD

Abstract #LBA20: TRIBE2: A phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts)
Featured Expert: Chiara Cremolini, MD

Abstract #463P: Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): Final results from the prospective, observational CORRELATE study
Featured Expert: Juan Manuel O’Connor, MD

Abstract #464P: Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
Featured Expert: Julien Taїeb, MD, PhD

Abstract #466P: Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 – REGOLD
Featured Expert: Thomas Aparicio, MD

Hepatocellular Carcinoma

Abstract #LBA26: Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)
Featured Expert: Michael J. Pishvaian, MD, PhD

Abstract #710P: Practice patterns and deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): Final analysis of OPTIMIS in Europe and Canada
Featured Expert: Jean-Luc Raoul, MD, PhD

Head & Neck

Abstract #LBA8_PR: KEYNOTE-048: Phase 3 study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Featured Expert: Barbara Burtness, MD

Abstract #1045O: A phase II window of opportunity study of preoperative olaparib (O) with cisplatin (C) or durvalumab (D) or olaparib alone in in patients with operable squamous cell head and neck carcinoma (HNSCC) (OPHELIA)
Featured Expert: Amanda Psyrri, MD, PhD

Melanoma

Abstract #LBA42: OpACIN-neo – A multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO)
Featured Expert: Christian U. Blank, MD, PhD

Abstract #LBA45: Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy
Featured Expert: Antoni Ribas, MD, PhD

 Abstract #1265P – Phase 1b/2 study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy
Featured Expert:  Antoni Ribas, MD, PhD 

Abstract #LBA47: Initial results from a phase 3b/4 study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511)
Featured Expert: Celeste Lebbé, MD

 Abstract #1244O: KEYNOTE-022 Part 3: Phase 2 randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma
Featured Expert: Paolo A. Ascierto, MD

Abstract #1248PD: Efficacy of pembrolizumab (Pembro) in patients (Pts) with advanced melanoma with stable brain metastases (BM) at baseline: A pooled retrospective analysis
Featured Expert: Omid Hamid, MD

NETs

Abstract #1307O: Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE 1509)
Featured Expert: Jaume Capdevila, MD, PhD

Abstract #1314P: Efficacy and safety of telotristat ethyl (TE) in combination with lanreotide (LAN) in patients with a neuroendocrine tumour and carcinoid syndrome (CS) diarrhoea (CSD): Meta-analysis of phase 3 double-blind placebo (PBO)-controlled TELESTAR and TELECAST studies
Featured Expert: Dieter Hörsch, MD, PhD 

Abstract #1316P: Impact of liver tumor burden on therapeutic effect of 177Lu-DOTATATE treatment in NETTER-1 study
Featured Expert: Jonathan Strosberg, MD

Abstract #1319P: Post-hoc analysis of CLARINET phase III study to investigate the influence of diabetic status on progression-free survival (PFS) of patients with neuroendocrine tumours (NETs) treated with lanreotide (LAN) or placebo (PBO)
Featured Expert: Filippo de Braud

Abstract #1331P: Tumour growth rate (TGR) when using lanreotide Autogel® (LAN) before, during and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumours (NETs)
Featured Expert: Vikas Prasad, MD, PhD

RCC

Abstract #LBA6_PR: JAVELIN Renal 101: a randomized, phase 3 study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)
Featured Expert: Manuela Schmidinger, MD

Abstract #LBA31: Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): results from a Phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)
Featured Expert: Brian I Rini, MD

Abstract #874P: Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis
Featured Expert: David McDermott, MD

Abstract #875P: Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (aRCC): CheckMate 214
Featured Expert: Brian I Rini, MD

This educational activity is supported by grants from Bayer HealthCare Pharmaceuticals, Inc.; Bristol-Myers Squibb; Ipsen; and Merck and Co, Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Barlesi has disclosed has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer, and Takeda. He also disclosed independent contracting for AbbVie, ACEA, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Eisai, Eli Lilly Oncology, F. Hoffmann-La Roche Ltd, Genentech, Ipsen, Ignyta, Innate Pharma, Loxo, Novartis, MedImmune, Merck, MSD, Pierre Fabre, Pfizer, Sanofi-Aventis, and Takeda. He also disclosed speaking and teaching for AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Cappuzzo has disclosed has disclosed board membership with AstraZeneca, MSD, Pfizer, and Roche. He also received consulting fees from AstraZeneca, MSD, Pfizer, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Herbst has disclosed has disclosed that he has received consulting fees from Abbvie Pharmaceuticals, AstraZeneca, Biodesix, Bristol-Myers Squibb, Eli Lilly and Company, EMD Serrano, Genentech/Roche, Heat Biologics, Jun Shi Pharmaceuticals, Loxo Oncology, Merck and Company, Nektar, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, and Tesaro. He received research support from AstraZeneca, Eli Lilly and Company, and Merck and Company. He has also served on Scientific Advisory Boards for the following companies: Neon Therapeutics, Infinity Pharmaceuticals, and NextCure. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Paz-Ares has disclosed has disclosed that he has received honoraria from Amgen, Astra-Zeneca, Bristol-Myers Squibb, Boehringer, Celgene, Incyte, Lilly, Merck, MSD, Novartis, Pfizer, Pharmamar, Roche, Servier, and Sysmex. He also disclosed institutional financial interests from AstraZeneca, Bristol-Myers Squibb, and Merck Sharp & Dohme. He has disclosed that he is a board member of Genomica. He also disclosed that he is a scientific chair and member of the Board of Asociación Española Contra el Cáncer (AECC; Majoir Spanish Anti-Cancer Charity). Furthermore, his wife has been an EMA SAG member, which concluded in June 2017. She also has received honoraria from July 2017 onwards from Amgen, Ipsen, Merck, Novartis, Pfizer, Roche, Servier, and Sanofi. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Amy Furedy, RN, OCN (scientific content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.